Media Center

Remove all filters

Oncology congress hub - Medical learning video

Oncology congress hub - Homepage

Oncology congress hub - Prostate cancer - Jorge’s story video

Oncology congress hub - Prostate cancer - Niels’ story video

Frontline DRd and DVMP

Dr Thierry Facon from Lille University Hospital and Dr Sonja Zweegman from Amsterdam University Medical Centre discuss MAIA and ALCYONE trial results. Date of prep: May 2022 iMR code: CP-319196

Haematology congress hub - Medical Learning - 1

Haematology congress hub - Medical Learning - 2

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - PAH and comorbidities: Connective tissue disease - audio 4

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - PAH and comorbidities: Connective tissue disease - 4

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - PAH and comorbidities: Obstructive sleep apnoea - audio 3

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - PAH and comorbidities: Obstructive sleep apnoea - 3

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - iPAH or COPD? audio 2

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - iPAH or COPD? - 2

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - PAH or HFpEF? audio 1

NET - Medical Education - PAH Academy - ExPHert Insights videos and podcasts - PAH or HFpEF? - 1

Fundamentals of pathology in NSCLC: An overview

Applications of testing modalities in NSCLC: Current and future practices

Applications of testing modalities in NSCLC: An overview of investigational techniques

Congress Pearls of AAD. Part 1: Updates on current psoriasis treatments

Congress Pearls of AAD. Part 2: Updates on atopic dermatitis

Congress Pearls of AAD. Part 3: Future outlooks of cutaneous inflammatory disorders

Management of connective tissue disease-associated pulmonary arterial hypertension: a multidisciplinary approach

Real world evidence in special populations

The future of Inflammatory Bowel Disease (IBD) Care

An overview of oncogenic‑driven non-small cell lung cancer (NSCLC)

Lung cancer: A heterogeneous disease

The future developments we might expect in CHD–PAH care

The future developments we might expect in CHD–PAH care

First biologic in Crohn’s disease: where to start?

Crohn’s disease management in motion: evolving outcomes

ECCO satellite symposium 2: “Winter warmer: hot topics in ulcerative colitis- Clinical Dilemmas”

ECCO satellite symposium 2: “Winter warmer: hot topics in ulcerative colitis – Future considerations”

ECCO satellite symposium 3: “IL-23 antagonists in ulcerative colitis”

ECCO satellite symposium 3: “Efficacy of IL-23 Blockade in Crohn’s disease”

ECCO satellite symposium 3: “Targeting the IL-23 pathway: from mechanism to clinical reality?”

Prostate Cancer OME Forum: Experts’ views on prostate cancer news from February 2022

Bladder Cancer OME Forum: Diving into Bladder Cancer News From February 2022!

Special considerations in paediatric CHD–PAH

Available treatment options for patients with CHD–PAH

Major subgroups within the CHD–PAH patient population

How best to screen for and diagnose PAH in patients with CHD

Special considerations in paediatric CHD–PAH

Available treatment options for patients with CHD–PAH

How best to screen for and diagnose PAH in patients with CHD

Major subgroups within the CHD–PAH patient population

Family planning: Accounting for patient’s future plans

Uncovering patient priorities: The conflict between COVID‑19 vaccination and treatment delay analysed

Mind and matter: Prognostic biomarkers and cognitive testing explored

The future is today: Reflecting on an optimised patient journey based on clinical scenarios

The patient at the centre: Updates on the hidden symptoms of Multiple Sclerosis

New developments in biomarkers and imaging

Disease course and treatment: An update

Multiple Sclerosis highlights from the EAN congress 2021

NET - Medical Education - Oncology - Janssen OME Med Ed Philosophy video 2022

Janssen-organised live webinar: Highlights of American College of Rheumatology (ACR) 2021

Joining the conversation on our evolving understanding of psoriasis and PsA management strategies: IL-23 pathway inhibition

GCC Psoriasis and Psoriatic Arthritis Masterclass: Plenary discussion and conclusion

GCC Psoriasis and Psoriatic Arthritis Masterclass: RHEUM parallel breakout

GCC Psoriasis and Psoriatic Arthritis Masterclass: Managing comorbidities

GCC Psoriasis and Psoriatic Arthritis Masterclass: New options for treating PsA

GCC Psoriasis and Psoriatic Arthritis Masterclass: Pathophysiology of domains of PsA

Virtual Glasgow PsA Masterclass: Session 3. Addressing the clinical complexity of PsA

Virtual Glasgow PsA Masterclass: Session 2. Management and strategies for coordinated and timely PsA care

Virtual Glasgow PsA Masterclass: Session 1. The current state of PsA, pathogenesis and imaging

Virtual Glasgow PsA Masterclass: Introduction

Beyond PsA: rheumatoid arthritis, spondyloarthritis and connective tissue diseases

Beyond PsO:skin immune-mediated inflammatory diseases

Interactive case-based discussions: diagnosis, treatments, and comorbidity managements

Psoriatic Arthritis treatment options

Collaboration and early referral of PsA and Current treatment options in PsO

Reasons to believe in IL-23 inhibition in psoriasis and PsA: it takes two to tango

Janssen Organized Satellite Symposium at WPPAC: Where do we begin? The key role of the IL-23 pathway in psoriasis and psoriatic arthritis

Janssen-Sponsored Satellite Symposium at the 2021 ESDR Annual Meeting: Joint decisions: towards comprehensive management of psoriasis and psoriatic arthritis

Janssen-Sponsored Satellite Symposium at the 2021 ESDR Annual Meeting: Detection and management of psoriatic arthritis: spot the signs, act fast

Janssen-Sponsored Satellite Symposium at the 2021 ESDR Annual Meeting: From research insights to therapeutic success: targeting the IL-23 pathway in the skin

Janssen-Sponsored Satellite Symposium at the ESDR 2021: Repainting the psoriasis picture: a fresh take on IL-23 and TRM in the skin

Janssen-Sponsored Satellite Symposium at the 2021 ESDR Annual Meeting - Welcome and introduction

Janssen-Sponsored Satellite Symposium at the 30th EADV Virtual Congress 2021: The art of joint forces: crafting psoriatic arthritis care for dermatologists

Janssen-Sponsored Satellite Symposium at the 30th EADV Virtual Congress 2021: Diving deep: harnessing the potential of the IL-23 pathway

Janssen-Sponsored Satellite Symposium at the LUPUS & CORA 2021 Congress Connecting the dots: what do we need to know to address the unmet needs in SLE?

Workshop 4: Managing Inflammatory Bowel Disease (IBD) comorbidities

Workshop 3: Long-term safety of biologics in Inflammatory Bowel Disease (IBD)

Workshop 2: Managing EIMs in Inflammatory Bowel Disease (IBD)

Workshop 1: Imaging in Inflammatory Bowel Disease (IBD)

Plenary session 2 & 3: Optimizing long-term outcomes of UC management & The future of IBD management: what’s next

Plenary session 1: Early choices in Crohn’s Disease (CD) management

Targeting the IL-12/23 pathways in Inflammatory Bowel Disease (IBD)

Is it applicable to daily clinical practice?

How good have we become in predicting outcomes?

Ulcerative Colitis (UC): new drugs, new targets, and better outcomes?

Dynamic management of Crohn’s Disease (CD): reaching a new dimension in patient care

Taking the long view in Inflammatory Bowel Disease (IBD)

Making waves in CD care: an update on the SEAVUE trial

How real-world ustekinumab evidence is helping us answer clinical questions

Symposium 2 - Targeting IL-12/23 in ulcerative colitis: from evidence to bedside

Symposium 1 - Planning the patient’s journey to success in Crohn’s disease

State of Play in Advanced Prostate Cancer: A Multi-disciplinary Expert Discussion

A review of prostate cancer in 2021